Advertisement

Pharmaceutical Research

, Volume 26, Issue 4, pp 855–864 | Cite as

Solubility of Small-Molecule Crystals in Polymers: d-Mannitol in PVP, Indomethacin in PVP/VA, and Nifedipine in PVP/VA

  • Jing Tao
  • Ye Sun
  • Geoff G. Z. Zhang
  • Lian Yu
Research Paper

Abstract

Objective

Amorphous pharmaceuticals, a viable approach to enhancing bioavailability, must be stable against crystallization. An amorphous drug can be stabilized by dispersing it in a polymer matrix. To implement this approach, it is desirable to know the drug’s solubility in the chosen polymer, which defines the maximal drug loading without risk of crystallization. Measuring the solubility of a crystalline drug in a polymer is difficult because the high viscosity of polymers makes achieving solubility equilibrium difficult.

Method

Differential Scanning Calorimetry (DSC) was used to detect dissolution endpoints of solute/polymer mixtures prepared by cryomilling. This method was validated against other solubility-indicating methods.

Results

The solubilities of several small-molecule crystals in polymers were measured for the first time near the glass transition temperature, including d-mannitol (β polymorph) in PVP, indomethacin (γ polymorph) in PVP/VA, and nifedipine (α polymorph) in PVP/VA.

Conclusion

A DSC method was developed for measuring the solubility of crystalline drugs in polymers. Cryomilling the components prior to DSC analysis improved the uniformity of the mixtures and facilitated the determination of dissolution endpoints. This method has the potential of providing useful data for designing physically stable formulations of amorphous drugs.

KEY WORDS

amorphous pharmaceuticals glass transition polymer dispersion PVP PVP/VA solubility 

Notes

Acknowledgment

We thank Abbott Laboratories for supporting this work and Dr. Feng Qian of BMS for the helpful discussions about the T end/T g diagrams.

References

  1. 1.
    M. Vasanthavada, W. Tong, Y. Joshi, and M. S. Kislalioglu. Phase behavior of amorphous molecular dispersions I: determination of the degree and mechanism of solid solubility. Pharm. Res. 21:1598–1606 (2004).PubMedCrossRefGoogle Scholar
  2. 2.
    M. Vasanthavada, W. Tong, Y. Joshi, and M. S. Kislalioglu. Phase behavior of amorphous molecular dispersions II: role of hydrogen bonding in solid solubility and phase separation kinetics. Pharm. Res. 22:440–448 (2004).CrossRefGoogle Scholar
  3. 3.
    P. J. Marsac, S. L. Shamblin, and L. S. Taylor. Theoretical and practical approaches for prediction of drug–polymer miscibility and solubility. Pharm. Res. 23:2417–2426 (2006).PubMedCrossRefGoogle Scholar
  4. 4.
    P. J. Marsac, T. Li, and L. S. Taylor. Estimation of drug–polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm. Res. in press (2008).Google Scholar
  5. 5.
    R. Mohan, H. Lorenz, and A. S. Myerson. Solubility measurement using differential scanning calorimetry. Ind. Eng. Chem. Res. 41:4854–4862 (2002).CrossRefGoogle Scholar
  6. 6.
    K. Park, J. M. B. Evans, and A. S. Myerson. Determination of solubility of polymorphs using differential scanning calorimetry. Cryst. Growth Des. 3:991–995 (2003).CrossRefGoogle Scholar
  7. 7.
    R. Tamagawa, W. Martins, S. Derenzo, A. Bernardo, M. Rolemberg, P. Carvan, and M. Giulietti. Short-cut method to predict the solubility of organic molecules in aqueous and nonaqueous solutions by differential scanning calorimetry. Cryst. Growth Des. 6:313–320 (2006).CrossRefGoogle Scholar
  8. 8.
    V. Andronis, and G. Zografi. Crystal nucleation and growth of indomethacin polymorphs from the amorphous state. J. Non-Cryst. Solids. 271:236–248 (2000).CrossRefGoogle Scholar
  9. 9.
    V. Andronis, and G. Zografi. Molecular mobility of supercooled amorphous indomethacin, determined by dynamic mechanical analysis. Pharm. Res. 14:410–419 (1997).PubMedCrossRefGoogle Scholar
  10. 10.
    M. Yoshioka, B. C. Hancock, and G. Zografi. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J. Pharm. Sci. 83:1700–1705 (1994).PubMedCrossRefGoogle Scholar
  11. 11.
    T. Wu, and L. Yu. Origin of enhanced crystal growth kinetics near Tg probed with indomethacin polymorphs. J. Phys. Chem. B. 110:15694–15699 (2006).PubMedCrossRefGoogle Scholar
  12. 12.
    S. R. Vippagunta, K. A. Maul, S. Tallavajhala, and D. J. W. Grant. Solid-state characterization of nifedipine solid dispersions. Int. J. Pharm. 236:111–123 (2002).PubMedCrossRefGoogle Scholar
  13. 13.
    N. Zajc, A. Obreza, M. Bele, and S. Srcic. Physical properties and dissolution behaviour of nifedipine/mannitol solid dispersions prepared by hot melt method. Int. J. Pharm. 291:51–58 (2005).PubMedCrossRefGoogle Scholar
  14. 14.
    I. Sugimoto, A. Kuchiki, and H. Nakagawa. Stability of nifedipine–polyvinylpyrrolidone coprecipitate. Chem. Pharm. Bull. 29:1715–1723 (1981).PubMedGoogle Scholar
  15. 15.
    H. Ishida, T. Wu, and L. Yu. Sudden rise of crystal growth rate of nifedipine near Tg without and with polyvinylpyrrolidone. J. Pharm. Sci. 96:1131–1138 (2007).PubMedCrossRefGoogle Scholar
  16. 16.
    L. S. Taylor, and G. Zografi. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm. Res. 14:1691–1698 (1997).PubMedCrossRefGoogle Scholar
  17. 17.
    T. Matsumoto, and G. Zografi. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization. Pharm. Res. 16:1722–1728 (1999).PubMedCrossRefGoogle Scholar
  18. 18.
    T. Miyazaki, S. Yoshioka, Y. Aso, and S. Kojima. Ability of polyvinylpyrrolidone and polyacrylic acid to inhibit the crystallization of amorphous acetaminophen. J. Pharm. Sci. 93:2710–2717 (2004).PubMedCrossRefGoogle Scholar
  19. 19.
    K. J. Crowley, and G. Zografi. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability. J. Pharm. Sci. 91:492–507 (2002).PubMedCrossRefGoogle Scholar
  20. 20.
    L. Yu, D. S. Mishra, and D. R. Rigsbee. Determination of the glass properties of d-mannitol using sorbitol as an impurity. J. Pharm. Sci. 87:774–777 (1998).PubMedCrossRefGoogle Scholar
  21. 21.
    L. Yu, J. Huang, and K. J. Jones. Measuring free-energy difference between crystal polymorphs through eutectic melting. J. Phys. Chem. B. 109:19915–19922 (2005).PubMedCrossRefGoogle Scholar
  22. 22.
    L. Yu. Nucleation of one polymorph by another. J. Am. Chem. Soc. 125:6380–6381 (2003).PubMedCrossRefGoogle Scholar
  23. 23.
    J. Tao, and L. Yu. Kinetics of cross-nucleation between polymorphs. J. Phys. Chem. B. 110:7097–7101 (2006).Google Scholar
  24. 24.
    M. K. Mapes, S. F. Swallen, and M. D. Ediger. Self-diffusion of supercooled o-terphenyl near the glass transition temperature. J. Phys. Chem. B. 110:507–511 (2006).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.School of Pharmacy and Department of ChemistryUniversity of Wisconsin, MadisonMadisonUSA
  2. 2.Solid State SciencesGlobal Pharmaceutical R & D, Abbott LaboratoriesNorth ChicagoUSA

Personalised recommendations